Fujifilm has completed its acquisition of Biogen’s large-scale biologics manufacturing site in Hillerød, Denmark, near Copenhagen, for approximately $890 million.

With the closing of this transaction, the Hillerød manufacturing site is the fourth biopharmaceutical manufacturing site of Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm and a contract development and manufacturing organization with expertise in the development and manufacture of biologics and advanced therapies. The Hillerød manufacturing site will change its name to Fujifilm Diosynth Biotechnologies Denmark ApS once all regulatory procedures are completed.

The site consists of a campus housing a large-scale production facility equipped with six 15,000-liter bioreactors for the manufacture of cell-culture-derived biologics for clinical and commercial use. There are close to 800 employees in the Hillerød campus, which also houses an assembly, labeling, and packaging facility, quality-control laboratories and warehouses. The products manufactured under Biogen at the site will continue to be supplied under Fujifilm ownership.

Source: Fujifilm